

MISSION STATEMENT

Putting people with lupus at the center of all we do, the Lupus Research Alliance drives the discovery and development of next generation lupus diagnostics and curative treatments through innovative research and collaborations.

The Lupus Research Alliance (LRA) has always placed people with lupus at the center, and in 2023, we elevated this commitment even further in our quest to free the world of lupus. Through funding transformative research, forging unique collaborations, breaking down barriers to health equity and partnering with the biopharmaceutical industry, the LRA remains steadfast in our goal to improve the lives of those living with lupus by finding new treatments, and one day, cures.

AN EXTRAORDINARY YEAR OF PROGRESS

In 2023, LRA invested \$41 million in novel lupus research, for a cumulative total of over \$286 million supporting more than 560 individual research awards since our founding in 1999. Importantly, over the years, your support has helped deliver new treatments, and brought us close to transformative breakthroughs.

Lupus Therapeutics (LT), the clinical research affiliate of the LRA, which oversees the Lupus Clinical Investigators Network (LuCIN), established collaborations and partnerships with numerous biopharmaceutical companies, focusing on promising therapies in all phases of development, including trials in major unmet areas such as cutaneous (skin related) lupus and lupus nephritis (kidney related).

As the only lupus research organization that spans the full research continuum, the LRA remains committed to accelerating treatments, diagnostics, and better care for people living with lupus. Read on for highlights showcasing how LRA is offering real hope for people with lupus and setting the stage for what is possible in the years ahead.

ONE STEP CLOSER TO BETTER TREATMENTS AND POTENTIAL CURES

Collaboration was an underlying theme contributing to success in 2023. The LRA launched significant and game-changing initiatives this past year, while continuing to advance the dialogue around lupus and fund critical breakthrough research. These efforts have created a remarkable framework to accelerate research and transform the future of those living with lupus today.

- Announced the **Lupus Accelerating Breakthroughs Consortium (Lupus ABC)** convening people with lived lupus experience, researchers, scientists, advocacy groups, industry and government stakeholders, including the FDA to address the most urgent challenges and advance safer treatments for people with lupus.
- Launched the **Lupus Nexus**, a unique lupus registry, biorepository, and information exchange platform that drives in-depth research to further the understanding and treatment of lupus, along with its key component, the **Lupus Landmark Study**, the largest of its kind longitudinal lupus study.
- Supported **pioneering research on CAR T cell therapies** that has led to the most dramatic, albeit still preliminary, clinical trial benefits in lupus yet.
- Established **Lupus Therapeutics Healthcare Provider Directory™**, a first-of-its-kind initiative that connects people living with lupus to state-of-the-art care and clinical research opportunities.
- Continued to build on core programs that address health equity, including expanding our **Patient Advocates for Lupus Studies (PALS)** program and progressing on **Project CHANGE**, our newest health equity initiative, all designed to break down barriers to care and diversify research participation.

As our President and CEO Albert T. Roy notes, "While we have achieved much in 2023, we will never be satisfied until the promise of individualized treatments is realized and each person living with this challenging disease has the chance to be the best version of themselves."

Board of Directors

We extend our sincere gratitude and appreciation to our Board of Directors, who fund all our administration and fundraising expenses. Their ongoing generosity allows us to commit 100% of all other donations to support lupus research programs.

Ira Akselrad, Co-Chairman
Richard K. DeScherer, Co-Chairman,
In Memorium
Anna Fisch, Secretary
Joseph Mauriello, Treasurer
Jim Andrew
Bishop Rudy V. Carlton
William "Willie" Colon
Jennifer Dakin
Thomas Daniel, MD
Jennie L. DeScherer
Katey Driscoll
Sir Marc Feldmann, FRS
Moti Ferder
Joe Germanotta
David M. Kies
Daniel M. LaVecchia
Veronica Vargas Lupo
Molly McCabe
Nadeem Meghji
William J. Mulvihill
Nidhi Patel
Robert Seder, MD
Daniel J. Wallace, MD, FACP, MACR
Julius Williams
William J. Wolfe
Spencer Zwick

Officers

Albert T. Roy, President & CEO
Stacie Bell, PhD, Executive Vice
President, Lupus Therapeutics, LLC
Luke Easley, VP, Human Resources
and Administration
Penny Mitchell, VP, Marketing and
Communications
Andrea J. O'Neill, VP, Chief
Development Officer
Debra Rose, VP, Chief Financial Officer
Teodora Staeva, PhD, VP, Chief
Scientific Officer

Scientific Advisory Board

Gary A. Koretzky, MD, PhD Chair
Laurent Arnaud, MD, PhD
Roberto Caricchio, MD
Andy Chan, MD, PhD
Mary Collins, PhD
Nancy Gonzalez
Judith James, MD, PhD
Alfred Kim, MD, PhD
Josef Penninger, MD, PhD
David J. Rawlings, MD
Jason Williams



Only research can improve treatment and lead to a cure. I truly believe that, with every gift you give and every new research project the LRA funds, we're getting closer to the day when neither I, nor anyone else, will need to fear lupus again."



Jacquelyn Smyth
LRA Young Leaders Board Member

OUR COMMUNITY IS OUR INSPIRATION

Our vibrant community has always been at the center of all we do, and our inspiration to drive the LRA mission forward. In 2023, we told the stories of countless people living with lupus to help demonstrate the complexity of this disease and offer hope to millions. Our signature fundraising program, *ManyOne Can Walk with Us to Cure Lupus*, remains strong and a testament that our community is united. Every year, thousands of Walkers join our Walks to raise money that directly goes to fund breakthrough research. Last year was no different. Walkers from all over, representing all walks of life, raised over \$1.1 million for lupus research. Thousands more helped advance our mission by participating in clinical research, advocating for more public funding for lupus research, and educating their communities about lupus.

EARNING EXCEPTIONAL RATINGS AS ONE OF THE MOST TRUSTED HEALTH ORGANIZATIONS

LRA continues to earn exceptional recognition as one of the best charities worldwide. We are proud to have earned four out of four stars by Charity Navigator, the Gold Seal of Transparency from Guidestar, recognition as a BBB Wise Giving Accredited Charity and a "Top Rated" status with an "A" ranking from nonprofit evaluator CharityWatch.

The following is an overview of the Lupus Research Alliance's income and expenditures for the fiscal year ended December 31, 2023.

Revenue & Other Support:

Contributions	\$ 41,038,661
Other Support	\$ 7,048,797
Total Revenue & Other Support:	\$48,087,458

Program Expenditures:


Research	\$ 14,914,820
Scientific programs	\$ 12,221,275
Public policy	\$ 761,506
Total Program Expenditures:	\$27,897,601

Administration Expenditures: \$ 3,107,200*

Fundraising Expenditures: \$ 3,609,881*

End of Year Net Asset Balance: \$75,313,644

*The LRA's Supporting Services are covered by donations from its Board of Directors.



The LRA contracts Lutz and Carr, CPA's as its independent auditor. A complete copy of the audited financial statements of the LRA for the year ended December 31, 2023, together with the independent auditor's report thereon, may be obtained through a written request to the LRA's national office and is also available on the LRA website; lupusresearch.org. The LRA is tax-exempt under 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible to the extent allowed by law.